Warner-Chilcott Back On The Block: Buy-Out Offer Values Firm At $2.7 Bil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Private equity group has approached company about possible bid. Proposal comes a year after Warner-Chilcott/Galen held negotiations with another pharma company about a merger.
You may also be interested in...
Warner Chilcott Buyout Values Women’s Health Rx Firm At $3 Bil.
Buyout by DLJ and J.P. Morgan investment groups will complete transformation of U.K. company into U.S.-focused specialty women’s health firm. Investor group plans to retain current Warner Chilcott management following sale.
Warner Chilcott Buyout Values Women’s Health Rx Firm At $3 Bil.
Buyout by DLJ and J.P. Morgan investment groups will complete transformation of U.K. company into U.S.-focused specialty women’s health firm. Investor group plans to retain current Warner Chilcott management following sale.
Femtrace Launch Planned For Early 2005
Warner Chilcott's hormone therapy clears FDA for the treatment of the vasomotor symptoms of menopause. Approval is not granted for a vulvar-vaginal atrophy indication, however. The company will use part of its 400-person U.S. sales force to market the product.